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A genetic polymorphism of the gene encoding angiotensin- 
converting enzyme has recently gained wide notoriety after it 
was reported to represent a risk factor for myocardial infarc- 
tion (1). In a retrospective study, patients with a history of 
myocardial infarction were found to carry the DDt genotype 
more frequently than control subjects, in whom the DI and II 
genotypes were more common. The genetic mutation respon- 
sible for the D and I alleles, identified by the absence or 
presence, respectively, of a nonsense deoxyribonucleic acid 
domain, is unlikely to be of direct pathogenetic importance but 
may serve as marker for a putative disease-relevant mutation 
elsewhere in the gene. Although there can be little doubt about 
the importance of heritable factors in the etiology of cardio- 
vascular disease (we all know too well the prognostic mpact of 
a positive family history), the complex nature of these disor- 
ders makes the dissection of particular contributing enes a 
dauntingly difficult endeavor. Therefore, the reported associa- 
tion of a variant of the angiotensin-converting enzyme gene 
with myocardial infarction was hailed as an important advance- 
ment on the road toward understanding the role of genetic 
factors in a complex, polygenic disease of major epidemiologic 
proportions. 
Angiotensin-converting enzyme polymorphism and cardio- 
vascular disorders. Since then, a growing number of small 
studies continue to be published that examine the association 
of the angiotensin-converting e zyme genotype not only with 
ischemic heart disease, but a variety of conditions ranging from 
hypertension to coronary artery restenosis, cardiac hypertro- 
phy, pulmonary hypertension, diabetes and nephropathy. Al- 
most all of these studies were performed inlimited numbers of 
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patients and control subjects, and the results have been 
variable and even contradictory; for example, the reported 
association of the DD genotype with early death (2) (presum- 
ably from hypertension-related complications) and the con- 
comitant finding of an association of the DD genotype with a 
life expectancy of>100 years (3) (in a study in centigenarians). 
The present issue of the Journal features two more reports on 
the topic (4,5). They examine, in small samples, the association 
of the angiotensin-converting e zyme D/I polymorphism with 
two very different cardiovascular disorders. The report by 
Montgomery etal. (4), with negative findings, investigates the 
relative frequencies ofthe D and I alleles among subjects with 
idiopathic dilated cardiomyopathy, a relatively infrequent dis- 
order; the study by Pinto et al. (5) examines a common 
condition, postmyocardial nfarction remodeling of the left 
ventricle, and reports an association between the DD genotype 
and ventricular enlargement. How are we to interpret these 
results and the results of angiotensin-converting e zyme gen- 
otype screening in general? 
Rare, inherited diseases. All disease, indeed all biologic 
traits, are the result of an interaction between genes and 
environment. Diseases in which simple Mendelian transmis- 
sion across generations is evident within a family pedigree are 
commonly termed monogenetic diseases. They are rare, and 
their occurrence is determined predominantly b the presence 
of a mutation in one gene, and although their expression is 
modified to some extent by the effects of environmental f ctors 
and other genes (the "genetic background"), these effects are 
minor in comparison. Owing to the remarkable advances in 
molecular genetics made over the past decade, finding the 
causative gene in these "single"-gene disorders has become 
almost routine. In the cardiovascular field, several Mendelian 
disorders, such as hypertrophic cardiomyopathy, the long QT 
syndrome or familial hypercholesterolemia, have thus found 
their molecular explanation in the characterization f rare 
genetic mutations. However, given the fact that homozygosity 
for the angiotensin-converting e zyme D allele occurs in one 
third of the normal population, how could this genotype play a 
major pathogenetic role in so many serious conditions, partic- 
ularly in less common ones, such as idiopathic dilated cardio- 
myopathy? (4). We certainly would never expect the DD 
genotype to indicate the presence of a major gene causing or 
contributing to this disorder. However, it could indicate the 
presence of a modulating gene that, in a specific or nonspecific 
interaction with a putative major (and rare) disease gene, 
alters the expression of the phenotype. An analysis based on 
comparing genotype frequencies among roups of patients and 
control subjects is unlikely to detect such a modifying effect. 
Comparison of average disease severity among subjects with 
different genotypes using a quantitative ariable of left ventric- 
ular dysfunction may have been a better way to investigate his 
possibility. However, given the small number of patients it is 
still unlikely that the power of such an analysis would have 
been sufficient to detect a, presumably modest, effect of such a 
modulating genetic influence. On the basis of the present data 
©1995 by the American College of Cardiology 0735-1097/95/$9.50 
0735-1097(95)00147-V 
JACC Vol. 25, No. 7 LINDPAINTNER AND PFEFFER 1633 
June 1995:1632-3 EDITORIAL COMMENT 
(4), we can conclude, in agreement with Montgomery et al., 
that the D/I polymorphism does not represent a major gene 
causing dilated cardiomyopathy--not surprising, given the 
disparate frequencies of marker and disease. However, we 
cannot exclude a modulating effect of the angiotensin- 
converting enzyme genotype on the severity of the disease. 
Complex polygenetie disorders. Common diseases, among 
them many cardiovascular disorders of major public health 
importance, such a ischemic heart disease, hypertension a d 
stroke, are regarded as complex disorders. In contrast to rare 
hereditary disease, the genetic omponent is thought o be 
carried by several genes that show multifaceted interactions 
with a number of environmental f ctors. While the dissection 
of genetic factors involved in these diseases would be of far 
greater practical importance than is the understanding of any 
of the rare monogenetic diseases, the task is much more 
difficult. Because no single gene involved contributes a pre- 
dominant effect on phenotype, their detection represents a 
major challenge. Epidemiologists have long understood that 
the recognition of risk factors that exert modest effects re- 
quires the use of large-scale studies to obtain a sufficiently 
representative sample and appropriate power, and that selec- 
tion of proper control subjects is essential for the interpreta- 
tion of such studies. The need for both these ingredients grows 
as the specificity of a given putative disease marker declines. 
Genetic markers used in association studies are no exception 
to this rule. The low specificity inherent to a marker that is 
more common than the condition studied, such as is the case 
for the DD genotype and postmyocardial infarction remodel- 
ing, therefore mandates large-scale studies, well beyond the 
size of the present study by Pinto et al. (5). Indeed, when the 
association between DD genotype and myocardial infarction 
and ischemic heart disease was recently reexamined using a 
more stringent study design and twice as many patients and 
control subjects (6) as originally examined (1), the previously 
reported findings could not be confirmed. The great variability 
of angiotensin-converting enzyme allele frequencies among 
normal white control subjects reported in various smaller 
studies indicates the presence of obvious selection bias and 
renders these studies uninterpretable (7). Moreover, the wide 
variety of biologically seemingly unrelated conditions that have 
been reported in association with the DD genotype might also 
raise suspicions about he reliability of these reports. Because 
of the small sample included in the present study (5) (the 
analysis of subgroups i a particularly dangerous practice), the 
data pointing to a role of the DD genotype in myocardial 
remodeling can only be viewed as provocative but not conclu- 
sive. Pinto et al. (5) acknowledge this and appropriately point 
out that their findings will have to stand the test of a much 
larger investigation. 
Conclusions. The increasingly widespread availability and 
easy applicability of molecular genetic tools provides the 
research community with a formidable opportunity o, at long 
last, begin uncovering the heritable component of complex 
diseases. In many cases, borne out of practical necessity and 
patient resources at hand, these tools may not be applied with 
the stringency that an epidemiologic geneticist may deem 
appropriate. However, as long as we view the data with critical 
reservation, and as long as we remember that crying wolf does 
not mean that one of these days the cry won't be for real, 
dissemination f such studies is vital to stimulate the field, to 
usher in new developments and to generate new hypotheses 
that eventually will be tested in more robust study designs. 
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